AMAgnieszka Morawa

Agnieszka Morawa

*This is an algorithmically generated author record based on publicly available information.

Agnieszka Morawa has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of climate change on the epidemiology of tick-borne encephalitis in Europe – a narrative review

    by Julia Maria Kuczkowska, Zuzanna Michalska, Judyta Bordakiewicz, Donata Pokorska, Julia Świechowska, Ingrid Samberger, Zuzanna Zarzycka, Magdalena Wiciak, Sonia Mojzyk, Agnieszka Morawa

    Introduction and objective: Tick-borne encephalitis (TBE) is an important viral infection caused by Flavivirus, primarily transmitted by Ixodes ricinus ticks. Its incidence and geographic range are increasing across Europe. The aim of the review is to assess currently available evidence on...

  • Open Access

    LIVING ALONGSIDE DISABILITY: THE MENTAL HEALTH RISK IN SIBLING RELATIONSHIPS. A REVIEW

    by Donata Pokorska, Judyta Bordakiewicz, Agnieszka Morawa, Sonia Mojzak, Zuzanna Michalska, Julia Świechowska, Zuzanna Zarzycka, Julia Maria Kuczkowska, Ingrid Samberger, Magdalena Wiciak

    This review aims to examine the psychological, psychiatric, and social outcomes among siblings of pediatric patients affected by disabilities, encompassing mental, neurodevelopmental, genetic, oncological, and somatic disorders. Despite extensive research on patients, the experiences of siblings remain underexplored, although existing evidence suggests that they represent a vulnerable group at increased risk for mental health issues and decreased quality of life. A literature review was conducted focusing on studies published within the last five years to ensure accuracy and novelty. Findings indicate that siblings of affected youth frequently endure emotional distress, including anxiety, guilt, and helplessness, in addition to disturbances in family dynamics and reduced parental attention. Increased caregiving obligations often result in exhaustion, social limitations, and a perceived deprivation of childhood. Across conditions, sibling psychopathology emerged as a key mediator of reduced quality of life. While some siblings demonstrate adaptive mechanisms and develop prosocial traits, others remain at risk of persistent psychological difficulties. Severity and type of illness influence outcomes, with particularly high levels of trauma- related symptoms and, in some instances, increased physical morbidity among siblings of children with cancer, whereas genetic conditions are associated with high rates of sleep disturbances. Siblings of individuals with disabilities are significantly affected across multiple domains of functioning. The burden is multifactorial and influenced by illness severity, family context, and individual characteristics. These findings highlight the need for systematic recognition of siblings’ needs and the implementation of targeted psychosocial interventions as part of comprehensive, family-centered care.

  • Open Access

    EFFICACY AND SAFETY OF MAVACAMTEN IN HYPERTROPHIC CARDIOMYOPATHY – A SYSTEMATIC REVIEW OF CURRENT CLINICAL STUDIES

    by Wiktoria Szkatuła, Marcin Schulz, Agnieszka Morawa, Dawid Studziński, Karolina Osińska, Michał Kulczak, Anna Kołcz

    Introduction: Hypertrophic cardiomyopathy (HCM) is an inherited condition characterized by sarcomeric hypercontractility, leading to dynamic left ventricular outflow tract (LVOT) obstruction in approximately 70% of patients. Mavacamten, a first-in-class selective cardiac myosin inhibitor, addresses the underlying molecular cause by reducing excessive actin-myosin cross-bridge formation. Aim: To evaluate the clinical efficacy and safety of mavacamten in symptomatic obstructive HCM (oHCM) using data from randomized trials and real-world studies. Methods: A systematic search of PubMed, Embase, and Cochrane Library identified 110 publications. Following predefined criteria, 44 studies were included in the final analysis, including pivotal phase III trials (EXPLORER-HCM, VALOR-HCM) and long-term extensions. Results: Mavacamten demonstrated a significant reduction in LVOT gradients (mean reduction of ~47 mmHg in EXPLORER-HCM) and improved quality of life, with KCCQ-CSS scores increasing by an average of 14.2 points. Between 60% and 80% of patients achieved ≥1 NYHA functional class improvement. In the VALOR-HCM trial, approximately 90% of patients avoided invasive septal reduction therapy (SRT) through 128 weeks. The primary safety concern was a transient reduction in LVEF (<50%) occurring in 5–14% of patients, which was typically reversible with dose titration. Conclusion: Mavacamten is a transformative non-invasive therapy that shifts oHCM management from palliative care to mechanism-targeted treatment. While highly effective in improving hemodynamics and functional capacity, rigorous echocardiographic monitoring remains mandatory to ensure safety regarding systolic function.

  • Open Access

    CLINICAL CHARACTERISTICS AND PROGNOSTIC SIGNIFICANCE OF NON-DIPPER HYPERTENSION

    by Wiktoria Szkatuła, Marcin Schulz, Dawid Studziński, Agnieszka Morawa, Karolina Osińska, Michał Kulczak, Anna Kołcz

    Non-dipper hypertension, characterized by a nocturnal blood pressure (BP) decline of less than 10% relative to daytime means, represents a significant clinical phenotype associated with heightened cardiovascular morbidity and mortality. While conventional office measurements often fail to capture these variations, ambulatory blood pressure monitoring (ABPM) has emerged as the gold standard for assessing 24-hour BP variability and identifying circadian rhythm disruptions. This review synthesizes current evidence regarding the clinical profile, pathophysiology, and prognostic impact of the non-dipper pattern. The pathophysiology of non-dipper hypertension involves a complex interplay of autonomic dysregulation, nocturnal renin-angiotensin-aldosterone system hyperactivity, and impaired renal sodium handling. This profile is highly prevalent among patients with metabolic comorbidities, such as type 2 diabetes and obesity, where prevalence rates can reach up to 77%. Prognostically, the non-dipper pattern is a potent independent predictor of target organ damage, including left ventricular hypertrophy, stroke, and chronic kidney disease. Notably, each 5% reduction in nocturnal BP fall is associated with a 20% increase in cardiovascular mortality. Therapeutic management emphasizes personalized chronotherapy specifically bedtime dosing of antihypertensive agents alongside novel pharmacological options like SGLT2 inhibitors and ARNIs. Furthermore, lifestyle interventions such as sodium restriction and the treatment of sleep disorders are crucial for restoring the physiological circadian rhythm. Ultimately, systematic use of ABPM is essential for accurate risk stratification and the implementation of targeted therapies to reduce the global burden of cardiovascular events.

  • Open Access

    EFFECTIVENESS AND SAFETY OF ANTI-CGRP MONOCLONAL ANTIBODIES FOR MIGRAINE PREVENTION IN REAL-WORLD PRACTICE: A SYSTEMATIC REVIEW

    by Dawid Studziński, Marcin Schulz, Karolina Osińska, Agnieszk Morawa, Anna Kołcz, Michał Kulczak, Konrad Turczynowski, Kamil Turczynowski, Grzegorz Machelski, Jan Gajewski

    The transition from Phase III trials to real-world evidence (RWE) is critical for understanding monoclonal antibody (mAb) performance in complex, comorbid populations. This review evaluates the real-world effectiveness and safety of calcitonin gene-related peptide (CGRP) pathway inhibitors in routine clinical practice. A systematic search of PubMed (2021–2026) identified observational studies, including prospective registries (e.g., PEARL, GARLIT, MAB-MIG) and large-scale claims analyses, regarding erenumab, fremanezumab, galcanezumab, and eptinezumab. Synthesis of 32 studies (n > 1 million patients) demonstrates robust effectiveness across diverse populations. Real-world data confirm sustained ≥ 50% responder rates (ranging from 40%–75% in most cohorts) and significant reductions in acute medication use. Benefits were maintained over 12–36 months, even in patients with chronic migraine and medication overuse headaches. Large-scale analyses (MarketScan, Medicare) indicate that CGRP inhibitors are not associated with an increased risk of myocardial infarction or stroke compared to onabotulinumtoxinA, even in older adults. Switching between ligand and receptor targets remains an effective strategy for initial non-responders. RWE establishes that anti-CGRP mAbs provide durable effectiveness and high adherence in difficult-to-treat populations. The data confirm a favorable cardiovascular safety profile, supporting their role as a cornerstone of modern migraine prevention.

  • Open Access

    NEUROINFLAMMATION AFTER MUSCULOSKELETAL TRAUMA - MISSING LINK BETWEEN ORTHOPEDIC INJURY AND CHRONIC PAIN?

    by Agnieszka Morawa, Sonia Mojzyk, Judyta Bordakiewicz, Zuzanna Michalska, Donata Pokorska, Julia Świechowska, Zuzanna Zarzycka, Julia Maria Kuczkowska, Ingrid Samberger, Magdalena Wiciak

    Musculoskeletal injuries, such as fractures and whiplash, affect around 9 million people annually and are a major cause of disability. In many cases, pain persists despite tissue healing, which is not fully explained by traditional models. Increasing evidence suggests that neuroinflammation - the activation of the innate immune system in the peripheral and central nervous systems - may underlie chronic pain. It involves glial cell activation and the release of proinflammatory mediators, leading to central sensitization and maladaptive synaptic plasticity. To evaluate neuroinflammation as a potential “missing link” between orthopedic injury and chronic pain, and to identify therapeutic targets. A search of PubMed, Web of Science and Google Scholar was conducted. Included were randomized controlled trials, systematic review and meta-analyses of ankle sprain treatment and rehabilitation strategies. Neuroinflammation contributes to the transition from acute to chronic pain beyond tissue healing. Glial activation and mediators, such as TNF-α and IL-1β, drive central sensitization, while caspase cascades (caspase-1, -3, -6) regulate AMPA and NMDA receptor trafficking in the spinal cord, maintaining hypersensitivity. Clinical findings, including MRI studies of whiplash patients, demonstrate nerve root inflammation associated with hyperalgesia. Emerging therapies, such as transcutaneous vagus nerve stimulation (tVNS) and exosome-based approaches, show promise in modulating these processes. Neuroinflammation links musculoskeletal injury to persistent pain by combining immune activation and neural changes that sustain central sensitization. Understanding these mechanisms may help identify patients at risk and guide the development of treatments targeting neuroinflammation to prevent chronic pain.

  • Open Access

    MID-REGIONAL PRO-ADRENOMEDULLIN (MR-proADM) AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN EARLY SEPSIS: A NARRATIVE REVIEW

    by Julia Świechowska, Sonia Mojzyk, Magdalena Wiciak, Ingrid Samberger, Julia Maria Kuczkowska, Zuzanna Zarzycka, Donata Pokorska, Zuzanna Michalska, Judyta Bordakiewicz, Agnieszka Morawa

    Sepsis is a critical medical condition resulting from an inappropriate host response to infection, often leading to organ dysfunction and high mortality. Early diagnosis remains a significant clinical challenge due to the nonspecific nature of initial symptoms and the limited efficacy of conventional biomarkers. Commonly used markers, such as C-reactive protein (CRP) and procalcitonin (PCT), provide useful information on inflammation and bacterial infections but do not adequately reflect vascular dysfunction or predict clinical deterioration. Mid-regional proadrenomedullin (MR-proADM) has recently gained importance as a biomarker reflecting both inflammatory processes and impaired vascular integrity. As a stable fragment of proadrenomedullin, it indirectly represents the activity of adrenomedullin, a peptide involved in maintaining endothelial function and circulatory homeostasis. Evidence from observational studies indicates that MR-proADM levels increase early in the course of infection and correlate with disease progression, organ failure, and risk of death. Compared to traditional biomarkers, MR-proADM appears to offer better prognostic performance, particularly in identifying patients at risk of severe complications. Its association with endothelial damage and microcirculatory dysfunction makes it particularly relevant to the pathophysiology of sepsis. In summary, MR-proADM may be a valuable complement to existing diagnostic tools, aiding early risk stratification and clinical decision-making. Further studies are needed to standardize its use and confirm its role in routine practice.

  • Open Access

    MATERNAL OBESITY AS A DETERMINANT OF LONG-TERM OFFSPRING HEALTH: INSIGHTS FROM METABOLIC, CARDIOVASCULAR, AND NEURODEVELOPMENTAL PERSPECTIVES

    by Karolina Osińska, Agnieszka Morawa, Marcin Schulz, Dawid Studziński, Anna Kołcz, Michał Kulczak, Izabela Ochońska

    Introduction and Objective: The prevalence of maternal overweight and obesity has increased dramatically worldwide, posing significant risks for offspring health. Maternal obesity has been associated with multisystemic consequences, including metabolic, cardiovascular, neuroendocrine, renal, and immune disturbances. This review aims to synthesize current evidence on the impact of maternal obesity on offspring health and to identify potential mechanisms underlying these effects. Methods: A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science for studies published up to 2026. Both human epidemiological studies and experimental animal models were included to evaluate the effects of maternal obesity on offspring outcomes. Keywords included “maternal obesity”, “offspring health”, “developmental programming”, “metabolic disorders”, “neurodevelopment”, and “immunology”. Relevant studies were critically assessed, with particular focus on mechanisms, sex-specific effects, and long-term consequences. Results / Methodology: Evidence indicates that maternal obesity programs offspring health through multiple pathways, including altered metabolism, epigenetic modifications, inflammatory processes, and microbiome-mediated effects. Offspring of obese mothers exhibit higher risk of hypertension, insulin resistance, type 2 diabetes, dyslipidemia, impaired renal development, neurodevelopmental and behavioral disorders, and immune dysregulation. These effects are often sex-specific and may persist throughout childhood and adulthood. Both preconception and gestational interventions, including weight management and lifestyle optimization, can partially mitigate these risks. Conclusion: Maternal obesity is a major determinant of long-term multisystem health outcomes in offspring. Understanding the mechanisms of developmental programming is essential for developing preventive strategies, emphasizing the importance of maternal health optimization before and during pregnancy.

  • Open Access

    Ankle Sprain: A Common but Often Overlooked Injury – A Review of Causes, Treatment, and Rehabilitation

    by Agnieszka Morawa, Karolina Osińska, Marcin Schulz, Michał Kulczak, Dawid Studziński, Anna Kołcz

    Introduction: Ankle sprains are a common injury affecting millions of people worldwide. While many cases are mild, they can lead to chronic joint instability, functional limitations and an increased risk of recurrence. Sprains most commonly involve the lateral ligaments of the joint, particularly ATFL, and in more complex cases, may also affect other structures, resulting in the high treatment costs. Aim: The aim of this article is to present modern methods of diagnosis, treatment and rehabilitation of ankle sprains, including innovative therapies and technologies that support recovery. Methods: A search of PubMed, Web of Science and Google Scholar was conducted. Included were randomized controlled trials, systematic review and meta-analyses of ankle sprain treatment and rehabilitation strategies. Results: An ankle sprain, if not treated properly, can lead to chronic instability, functional limitations and the risk of recurrence. Early diagnosis, intervention are crucial. Modern therapeutic methods such as micro-needle knives, electroacupuncture and rehabilitation robots offer promising treatment options. Integration of traditional methods with innovative technologies can speed up rehabilitation, improve joint stability and reduce the risk of recurrence. Conclusion: An ankle sprain, despite its initially mild nature,can lead to long term functional consequences. Early diagnosis and appropriate therapeutic intervention are crucial to minimise the risk of chronic instability and other complications. Modern diagnostic technologies and biological therapies are promising treatment options, accelerating the rehabilitation process and improving functional outcomes. However, these innovative methods require further research and verification of the reliability of the results obtained, as they are still in the early stages of development.


  • Open Access

    NEPRILYSIN INHIBITORS (ARNI) IN THE TREATMENT OF CHRONIC HEART FAILURE — A SYSTEMATIC REVIEW AND CRITICAL APPRAISAL OF THE EVIDENCE

    by Marcin Schulz, Karolina Osińska, Dawid Studziński, Michał Kulczak, Anna Kołcz, Agnieszka Morawa

    Angiotensin receptor–neprilysin inhibitors (ARNI), with sacubitril/valsartan as the prototypical agent, have fundamentally transformed the pharmacological treatment paradigm of chronic heart failure (HF) [6,11,36,47,48,49,50]. This systematic review synthesizes the available clinical evidence, with a particular focus on the therapeutic efficacy of ARNI across the full continuum of left ventricular ejection fraction [3,4,17,50]. In patients with heart failure with reduced ejection fraction (HFrEF), pivotal randomized trials have consistently demonstrated the superiority of ARNI over conventional angiotensin-converting enzyme inhibitors in lowering cardiovascular mortality and HF-related hospitalizations, while also promoting favorable reverse myocardial remodeling [2,9,10,11,18,26,30,39,41,43,44,49]. In contrast, among individuals with preserved or mildly reduced ejection fraction, the principal clinical benefit is reduction in recurrent HF hospitalizations, with numerically greater treatment effects reported in women [1,3,7,18,23]. In addition, sacubitril/valsartan exhibits clinically relevant renoprotective effects and a favorable safety profile in complex patient populations, including those with diabetes mellitus or advanced chronic kidney disease [4,10,11,18]. Contemporary clinical guidelines position ARNI as a cornerstone of quadruple guideline-directed medical therapy, recommending early initiation during hospitalization and proactive dose up-titration to optimize clinical outcomes [7,8,11,13,21,31,47,48,49,50]. Addressing barriers to implementation—such as treatment-related hypotension and therapeutic inertia—remains essential to reduce the considerable global burden of heart failure [5,7,28,29,34,38].